On Invalid Date, Biolase (NASDAQ: BIOL) reported Q1 2023 earnings per share (EPS) of -$0.18, up 77.78% year over year. Total Biolase earnings for the quarter were -$5.85 million. In the same quarter last year, Biolase's earnings per share (EPS) was -$0.81.
As of Q2 2023, Biolase's earnings has grown year over year. Biolase's earnings in the past year totalled -$29.71 million.
What was BIOL's revenue last quarter?
On Invalid Date, Biolase (NASDAQ: BIOL) reported Q1 2023 revenue of $10.47 million up 2.96% year over year. In the same quarter last year, Biolase's revenue was $10.17 million.
What was BIOL's revenue growth in the past year?
As of Q2 2023, Biolase's revenue has grown 18.24% year over year. This is 12.83 percentage points higher than the US Medical Devices industry revenue growth rate of 5.42%. Biolase's revenue in the past year totalled $48.76 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.